First National Bank of Mount Dora Trust Investment Services Takes Position in Boston Scientific Corporation $BSX

Key Points

• First National Bank of Mount Dora Trust Investment Services acquired 134,736 Boston Scientific shares worth approximately $8.5 million, making BSX its 21st-largest holding and 1.8% of its portfolio. Institutional investors collectively own 89.07% of the company.
• Boston Scientific exceeded second-quarter expectations, reporting adjusted EPS of $0.86 and revenue of $5.44 billion, up 7.5% year over year. However, the company lowered its full-year outlook because of weakness in its electrophysiology and WATCHMAN businesses.
• Analysts maintain a broadly positive view, with a consensus “Moderate Buy” rating and average price target of $71.62, while Boston Scientific has authorized a $5 billion share-repurchase program covering up to 6.4% of outstanding shares.

First National Bank of Mount Dora Trust Investment Services purchased a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 134,736 shares of the medical equipment provider's stock, valued at approximately $8,455,000. Boston Scientific makes up approximately 1.8% of First National Bank of Mount Dora Trust Investment Services' portfolio, making the stock its 21st largest holding.

Other hedge funds have also bought and sold shares of the company. FWL Investment Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at about $26,000. Swiss RE Ltd. bought a new position in shares of Boston Scientific during the fourth quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $26,000. Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Boston Scientific in the first quarter valued at approximately $28,000. Finally, Sfam LLC bought a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $29,000. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on BSX shares. Mizuho reduced their price target on Boston Scientific from $90.00 to $70.00 and set an "outperform" rating on the stock in a research report on Wednesday, July 15th. Oppenheimer cut their target price on Boston Scientific from $90.00 to $85.00 and set an "outperform" rating for the company in a research report on Monday, July 27th. Evercore set a $65.00 price objective on shares of Boston Scientific in a research note on Monday, July 6th. The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a research report on Thursday, May 28th. Finally, Canaccord Genuity Group reduced their target price on Boston Scientific from $70.00 to $66.00 and set a "buy" rating on the stock in a report on Thursday. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $71.62.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted earnings of $0.86 per share and revenue of $5.44 billion, exceeding consensus estimates of $0.83 and $5.38 billion, respectively. Revenue increased 7.5% year over year, while management highlighted approximately 7% organic sales growth and a 15% increase in adjusted EPS. Boston Scientific Q2 earnings call highlights
• Positive Sentiment: Management’s multiyear restructuring plan is intended to improve efficiency and generate roughly $500 million in savings, supporting longer-term margins despite restructuring costs of up to $800 million. Reported workforce reductions are expected to affect operations in Ireland and Costa Rica. Boston Scientific restructuring cuts
• Positive Sentiment: Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year over year, with thrombectomy revenue rising 12.5% and embolization and access revenue increasing 20.0%. The results provide supportive operating momentum for Boston Scientific’s pending acquisition of Penumbra, although PEN will not issue full-year guidance during the transaction. Penumbra second-quarter financial results
• Neutral Sentiment: Analyst sentiment remains broadly constructive but more cautious: UBS reaffirmed a Buy rating with a $74 target, while TD Cowen and Truist maintained Buy ratings despite lowering targets to $56 and $57. Argus reiterated a Hold rating, and BTIG reduced its expectations.
• Negative Sentiment: Boston Scientific lowered its full-year outlook because of headwinds affecting its electrophysiology and WATCHMAN portfolios. Analysts also cited a reset in expectations for these businesses, limiting the near-term upside from the earnings beat. Boston Scientific lowered full-year guidance
• Negative Sentiment: A recall involving the Rapid Refill Continuous Injection System adds a product and execution risk, while the restructuring will create near-term charges before expected savings are realized. Boston Scientific earnings, recall and restructuring

Boston Scientific Stock Up 0.0%

Shares of NYSE:BSX opened at $46.75 on Monday. The company has a fifty day moving average of $46.13 and a 200-day moving average of $62.02. The company has a market capitalization of $69.48 billion, a PE ratio of 18.93, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.Boston Scientific's revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter last year, the business posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has initiated a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In other news, Director David C. Habiger purchased 2,250 shares of the business's stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares of the company's stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Edward J. Ludwig purchased 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares of the company's stock, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders bought 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.